TICAGRELOR 90mg. IP

A new class of antiplatelet agents (blood thinners) keeps blood flowing smoothly in the body. (Oestreich, 2014) Prevents platelets from sticking together and lessens the formation of harmful blood clots. Maintains blood flow in the body to help reduce the risk of another cardiovascular event. Exerts a faster onset of action and more potent inhibition of platelet aggregation than clopidogrel in acute coronary syndromes patients. (Robert F. Storey, 2010) A first‐line treatment for the prevention of blood clots in adult patients with acute coronary syndromes and in coronary artery disease patients who undergo percutaneous coronary intervention. (Charalambos Vlachopoulos, 2019) Possesses superior efficacy and greater antiplatelet effect than clopidogrel in acute coronary syndromes patients. (Robert F. Storey, 2010) Shows a significant improvement in aortic stiffness in patients with coronary artery disease. (Charalambos Vlachopoulos, 2019) Diminishes the rate of stroke, cardiovascular death, and myocardial infarction in subjects with acute coronary syndrome or a history of myocardial infarction.